

**Short-acting opioid analgesics for acute pain —
Clinical Criteria and duration of use**

Override(s)	Approval duration
Quantity Limit	<p>Prescribed by a dentist for dental procedure related pain: one month</p> <p>Initial request for newly prescribed chronic pain diagnosis: three months</p> <p>Maintenance Therapy for chronic pain: Additional prior authorization required for each additional six months</p> <p>Individuals receiving for terminal diagnosis and receiving palliative care/end-of-life therapy: Lifetime</p> <p>Individuals receiving for cancer pain related to active cancer therapy or sickle cell anemia: one year</p>

Medications	Quantity limit
<p>Benzhydrocodone-Acetaminophen tablets (4.08/325mg, 6.12mg-325mg, 8.16/325mg)</p> <p>Butalbital-APAP-Caffeine-Codeine – All oral formulations of the following: Butalbital/acetaminophen/caffeine/codeine Acetaminophen/caffeine/dihydrocodeine</p> <p>Butalbital-ASA-caffeine-codeine – All oral formulations of the following: Butalbital/aspirin/caffeine/codeine</p> <p>Codeine sulfate - All oral formulations of codeine sulfate</p> <p>Hydrocodone-Acetaminophen tablets (2.5mg-325mg, 5mg-300mg, 5mg-325mg, 7.5mg-300mg, 7.5mg-325mg, 10mg-300mg, 10mg- 325mg)</p>	<p>Three days' supply per fill: When prescribed by a dentist for dental procedure related pain.</p> <p>Seven days' supply per fill; 14 day's supply per 30 days: When prescribed by <i>other than</i> a dentist.</p>

Hydrocodone-Acetaminophen oral solution (2.5mg-108mg/5mL, 5mg-163mg/7.5mL, 5mg- 217mg/10mL, 7.5-325/15mL, 10mg-300mg/15mL, 10mg-325mg/15mL)

Hydrocodone-Ibuprofen – All oral formulations of hydrocodone/ibuprofen

Hydromorphone – All oral tablet and liquid formulations of immediate release hydromorphone

Meperidine - All oral formulations of meperidine

Morphine sulfate IR tabs and solution – All oral tablet and liquid formulations of immediate release morphine sulfate

Nucynta (tapentadol) – All oral formulations of immediate release Nucynta

Oxymorphone - All oral formulations of immediate release oxymorphone

Oxycodone – All oral formulations of immediate release oxycodone

Oxycodone-Acetaminophen tablets (2.5mg-300mg, 2.5mg-325mg, 5mg-300mg, 5mg-325mg, 7.5mg-300mg, 7.5mg-325mg, 10mg- 300mg, 10mg-325mg)

Oxycodone-Acetaminophen oral solution (5mg-325mg/5mL, 10mg-300mg/5mL)

Oxycodone-Aspirin tablets (4.8355mg-325mg)

Oxycodone-Ibuprofen tablets (5mg-400mg)

Pentazocine-naloxone - All oral formulations of pentazocine/naloxone

Acetaminophen-Cod #2 tablets (acetaminophen-codeine 300mg-15mg)

<p>Tylenol with codeine #3 tablets (acetaminophen-codeine 300mg-30mg)</p> <p>Acetaminophen-codeine oral solution, suspension 120-12mg/5mL, 300/12.5mL</p> <p>Tylenol With Codeine #4 Tablets (acetaminophen-codeine 300mg-60mg)</p> <p>Ultram, Tramadol HCl, Ultracet, Tramadol HCl- Acetaminophen, Seglentsis – All oral formulations</p>	
--	--

The Analgesic Opioid Prior Auth Form can be located here:
https://provider.amerigroup.com/docs/gpp/DC_CAID_AnalgesicOpioidPAForm.pdf

Approval criteria

Requests for greater than three days’ supply per fill of short-acting opioid analgesics when **prescribed by a dentist for dental procedure pain** may be approved for the following:

- I. Individual has undergone a procedure that is likely to result in severe pain for more than three days.

Individuals who are opioid naïve or have not had consistent utilization of opioid therapy in available prescription history will be limited to seven days’ supply per fill and 14 days’ supply per 30 days when prescribed by a provider other than a dentist.

Requests for greater than seven days’ supply per fill and greater than 14 days’ supply per 30 days of short-acting opioid analgesics when prescribed by *other than* a dentist may be approved for the following:

- I. Individual has a diagnosis of cancer related pain and/or is actively undergoing cancer treatment (provide diagnosis); **OR**
- II. Individual has a terminal condition and is receiving palliative/end-of-life care (provide diagnosis); **OR**
- III. Individual has a diagnosis of sickle cell anemia; **OR**
- IV. Individual is currently utilizing opioid therapy on a consistent basis for a chronic pain diagnosis; **AND**
 - A. Prescriber has consulted with individual regarding risks of opioid therapy; **AND**
 - B. Clear treatment goals have been defined and outlined as part of overall plan; **AND**
 - C. Prescriber has reviewed the prescription drug monitoring program (PDMP) to evaluate use of controlled substances (if available)

OR

- V. Individual is newly prescribed a short-acting opioid for a chronic pain diagnosis; **AND**
- A. Documentation has been provided regarding of one of the following:
 - i. Individual has had an inadequate response to alternative pharmacologic treatment options, such as but not limited to non-opioid analgesics;
OR
 - ii. Individual has contraindications to non-opioid analgesics (such as NSAID use in individuals with active ulcer condition/gastrointestinal bleeding, renal failure);
AND
 - B. Prescriber has consulted with individual regarding risks of opioid therapy; **AND**
 - C. Clear treatment goals have been defined and outlined as part of overall plan;
AND
 - D. Prescriber has reviewed the prescription drug monitoring program (PDMP) to evaluate use of controlled substances (if available).

Tramadol containing agents may be subject to the following age requirements via prior authorization:

- I. Individual is 18 years of age or older; **OR**
- II. Individual is 12 years of age or older and treating for pain conditions other than postsurgical removal of tonsils and/or adenoids. (FDA Safety Announcement 2017)

Codeine containing agents may be subject to the following age requirements via prior authorization:

- I. Individual is 12 years of age or older. (FDA Safety Announcement 2017)

NOTE: An FDA Safety advisory released on April 20, 2017 noted that the label for codeine containing agents would be updated to include a contraindication for use in treating pain or cough in children younger than 12 years. This is due to serious risks, including slowed or difficult breathing and death, which appear to be a greater risk in children younger than 12 years (<https://www.fda.gov/drugs/drugsafety/ucm549679.htm>).

Key references:

1. Clinical Pharmacology database online. Tampa, FL: Gold Standard, Inc.: 2021. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 16, 2021.
3. DrugPoints® System electronic version. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2021; Updated periodically.

Federal and state laws or requirements, contract language, and plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.